Bo-Lin Zhu

Bo-Lin Zhu

Auto-generated profile, based on publicly available information

Bo-Lin Zhu

Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2025 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
WLWang-Jian Li
Wang-Jian Li
LLLi-Ting Ling
Li-Ting Ling
YYYue Yao
Yue Yao
KTKai-Qing Tan
Kai-Qing Tan
BZBo-Lin Zhu
Bo-Lin Zhu
ZLZhong-guo Liang
Zhong-guo Liang
To evaluate 10-year survival outcomes of intensity-modulated radiotherapy (IMRT)-era locoregionally advanced nasopharyngeal carcinoma (NPC) treated with concurrent chemoradiotherapy (CCRT) ± adjuvant chemotherapy (AC), and assess the impact of AC on survival in high-risk and low-risk patients. This retrospective cohort study analyzed 477 non-metastatic NPC patients (2009–2012) treated with CCRT + AC (n = 315) or CCRT alone (n = 162). Risk stratification into high-/low-risk subgroups utilized a published prognostic model. Kaplan-Meier estimates compared 10-year overall survival (OS), locoregional failure-free survival (LFFS), distant metastasis-free survival (DMFS), and failure-free survival (FFS). The 10-year OS, DMFS, LFFS, and FFS rates for the entire cohort were 71.7 %, 81.4 %, 87.9 %, and 68.1 %, respectively. Compared to CCRT alone, CCRT + AC demonstrated no significant improvement in OS (70.9 % vs. 73.4 %; HR = 1.036, 95 % CI: 0.717–1.497, P = 0.849), LFFS (87.5 % vs. 88.7 %; HR = 1.176, 95 % CI: 0.642–2.154, P = 0.598), DMFS (79.4 % vs. 85.3 %; HR = 1.356, 95 % CI: 0.839–2.191, P = 0.211), or FFS (66.4 % vs. 71.5 %; HR = 1.133, 95 % CI: 0.803–1.599, P = 0.477). In high-risk patients, AC failed to enhance OS (62.7 % vs. 57.5 %; HR = 0.755, 95 % CI: 0.511–1.115, P = 0.156) or other survival endpoints. Notably, AC was associated with reduced OS (84.8 % vs. 94.1 %; HR = 3.319, 95 % CI: 0.966–11.401, P = 0.043) and FFS (77.8 % vs. 92.0 %; HR = 2.596, 95 % CI: 1.064–6.332, P = 0.029) in low-risk patients, while showing no benefit in LFFS or DMFS. The addition of AC to CCRT did not improve 10-year survival outcomes in locoregionally advanced NPC. Moreover, AC may adversely impact survival in low-risk patients, highlighting the need for risk-adapted therapeutic strategies.

13 September 2025 in European Journal of Cancer
Verified
Journal Article
Closed access
LLLi-Ting Ling
Li-Ting Ling
WLWang-Jian Li
Wang-Jian Li
YYYue Yao
Yue Yao
KTKai-Qing Tan
Kai-Qing Tan
BZBo-Lin Zhu
Bo-Lin Zhu
ZLZhong-guo Liang
Zhong-guo Liang

12 March 2026 in Translational Oncology
Verified
Journal Article
Open access
WLWang-Jian Li
Wang-Jian Li
FSFang Su
Fang Su
LLLi-Ting Ling
Li-Ting Ling
BZBo-Lin Zhu
Bo-Lin Zhu
BDBin Deng
Bin Deng
ZLZhong-guo Liang
Zhong-guo Liang
To develop a risk stratification model to identify high-risk locoregionally advanced nasopharyngeal carcinoma (NPC) susceptible to radiotherapy interruption (RTI) ≥5 days and evaluate whether induction chemotherapy (IC) mitigated the associated survival detriment. We retrospectively analyzed 820 patients treated with intensity-modulated radiotherapy, randomly allocated into training (n = 490) and validation (n = 330) cohorts. Prognostic factors for overall survival (OS) were screened using univariate and multivariate analyses. A Cox regression-based prognostic model was developed and evaluated via C-index and calibration plots. RTI ≥5 days impact on survival endpoints-OS, locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and failure-free survival (FFS)-was assessed across risk groups, with IC effect analyzed in high-risk patients using propensity score matching. A prognostic model incorporating age, T stage, N stage, and EBV-DNA >4000 copies/mL was established. The prognostic index (PI) stratified patients into high- and low-risk groups, with high-risk patients exhibiting significantly inferior survival in OS, DMFS, and FFS (all P < 0.05). The model demonstrated C-indices of 0.744 (training) and 0.658 (validation) for OS prediction, outperforming the 8th AJCC staging system. RTI ≥5 days significantly reduced OS in high-risk patients (training: HR 1.816, P = 0.034; validation: HR 2.310, P = 0.024) but not in low-risk patients. Importantly, IC ≥2 cycles eliminated RTI-associated survival differences in high-risk patients following confounding adjustment. The developed model effectively identified high-risk NPC patients vulnerable to RTI ≥5 days, with IC shown to mitigate this risk. These findings support the implementation of risk-stratified treatment strategies and proactive IC use to counter unavoidable treatment delays.